Senseonics Announces FDA Approval for a Non-Adjunctive Indication (Dosing Claim) for the Eversense® 90-day CGM System
7 June 2019
Senseonics Holdings, Inc a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with d
